In the past few weeks, FibroBiologics, Inc. (FBLG) has announced multiple important advancements, including HREC approval to conduct a Phase 1/2 trial of CYWC628 in diabetic foot ulcers (DFUs), filing an IND to seek clearance for a Phase 1/2 clinical trial of CYPS317 for the treatment of moderate to severe psoriasis, announcing positive preclinical results for a fibroblast therapy for degenerative disc disease, closing multiple registered direct offerings, and paying off all outstanding debt. Looking ahead to 2026, we anticipate the initiation of the Phase 1/2 trial in DFUs in the first quarter of 2026, the potential for IND clearance for CYPS317, and the advancement of CYMS101 toward an IND submission for the treatment of multiple sclerosis.
